表 2.
不同临床亚型患者血常规及淋巴细胞亚群分析
Analysis of routine blood test and lymphocyte subsets in patients with different clinical classifications
| Characteristic | Moderate (n=35) | Severe (n=39) | Critical (n=7) | P |
| Data are shown as x±s or M(P25, P75). | ||||
| Leukocyte/(×109/L) | 5.69±1.51 | 5.75±1.53 | 12.18±2.76 | < 0.001 |
| Neutrophil/% | 54.56±7.07 | 60.22±8.38 | 90.73±4.19 | < 0.001 |
| Neutrophil/(×10 9/L) | 2.95 (2.35, 3.51) | 3.36 (2.91, 3.66) | 11.49 (9.67, 12.72) | < 0.001 |
| Lymphocyte/% | 32.51±6.64 | 27.04±7.65 | 4.74±3.09 | < 0.001 |
| Lymphocyte/(×109/L) | 1.82±0.51 | 1.52±0.50 | 0.52±0.19 | < 0.001 |
| Monocyte/% | 9.38±2.14 | 9.35±2.06 | 3.87±1.32 | < 0.001 |
| Monocyte/(×109/L) | 0.53±0.16 | 0.54±0.20 | 0.46±0.17 | 0.693 |
| Eosinophil/% | 2.8 (1.9, 3.9) | 2.1 (1.5, 3.2) | 0.1 (0.05, 0.75) | < 0.001 |
| Eosinophil/(×109/L) | 0.17±0.11 | 0.17±0.17 | 0.05±0.06 | 0.010 |
| Basophil/% | 0.51±0.25 | 0.52±0.36 | 0.21±0.23 | 0.018 |
| Basophil/(×109/L) | 0.03 (0.02, 0.04) | 0.03 (0.01, 0.04) | 0.01 (0.01, 0.02) | 0.173 |
| CD3+CD19-T-cell/% | 74.00±7.03 | 73.72±10.14 | 64.84±14.87 | 0.125 |
| CD3+CD19-T-cell/(cells/μL) | 1 292±395 | 1 094±408 | 295±156 | < 0.001 |
| CD3-CD19+B-cell/% | 12.27±4.96 | 12.64±7.05 | 23.77±18.78 | 0.055 |
| CD3-CD19+B-cell/(cells/μL) | 225±126 | 180±101 | 110±91 | 0.033 |
| CD4+T-cell/% | 47.61±7.89 | 45.56±7.70 | 44.66±16.01 | 0.501 |
| CD4+T-cell/(cells/μL) | 838±304 | 675±260 | 212±145 | < 0.001 |
| CD8+T-cell/% | 23.08±6.06 | 25.73±9.69 | 18.86±11.80 | 0.216 |
| CD8+T-cell/(cells/μL) | 410±135 | 383±198 | 77±39 | < 0.001 |
| CD3-/CD16+CD56+NK cell/% | 12.99±6.85 | 12.95±6.24 | 10.13±8.54 | 0.584 |
| CD3-/CD16+CD56+NK cell/(cells/μL) | 212±106 | 185±101 | 39±28 | < 0.001 |
| T+B+NK cell/% | 99.25±0.52 | 99.33±0.51 | 98.74±0.95 | 0.054 |
| T+B+NK cell/(cells/μL) | 1 729±464 | 1 435±505 | 444±182 | < 0.001 |
| CD4+/CD8+ | 2.14±0.76 | 2.08±1.07 | 3.35±1.97 | 0.242 |